No Data
Earnings Flash: CareRx Q2 Diluted EPS $0.13, Up From $0.11 in 2023
CareRx Corp. Is Maintained at Buy by Desjardins Securities
CareRx Corp. Price Target Raised to C$4.00/Share From C$3.75 by Desjardins Securities
CareRx Brief: Dalton Will Be Succeeded by Jeff Watson, a Current Independent Director of the Board
CareRx Brief: Company Undertaking a Search for a New CFO; Davide Pernarella, Currently Vice President, Business Planning and Analysis at CareRx, Will Assume the Role of Interim CFO
CareRx Brief: Says Andrew Mok Will Step Down as Chief Financial Officer Effective June 7, 2024, to Pursue Another Employment Opportunity
No Data